Their activity against tumor-specific antigens was then determined with tetrazolium (MTT), chromium-51 (51Cr) release, or cell counting kit 8 (CCK8) assays, or by measuring cytokine levels (IFN-γ, TNFα, IL-2) with ELISA (Table 4). The gene discussed is IL2; the disease is neoplasm.